| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Mononucleosis Screen
MessageSerology
Test Code
LAB482
Alias/See Also
Mono, Infectious Mononucleosis, IM
CPT Codes
86308
Preferred Specimen
1 ml. serum (gold top SST tube)
Minimum Volume
50uL serum/plasma
Other Acceptable Specimens
Plasma (CPDA-1, heparin, or EDTA)
Instructions
LAB: Centrifuge and deliver to Serology for testing.
Transport Temperature
Do not repeatedly freeze and thaw samples.
Invert thawed samples several times just prior to testing.
Invert thawed samples several times just prior to testing.
Specimen Stability
Refrigerated 2 - 8° C : 48 hours
Frozen -20° C: 3 months
Frozen -20° C: 3 months
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Mildly hemolyzed whole blood specimens do not affect the test result
There are no known interfering substances that will affect the expected results.
There are no known interfering substances that will affect the expected results.
Methodology
One-step antibody test for IM uses direct solid-phase immunoassay technology for the qualitative detection of IM heterophile antibodies in human serum or plasma.
Setup Schedule
Available STAT.
Report Available
Same day
Limitations
A negative result may be obtained from patients at the onset of the disease due to antibody concentration below the sensitivity of this test kit. If symptoms persist or increase in intensity, the test should be repeated.
Some segments of the population who contract Infectious Mononucleosis do not produce measurable levels of heterophile antibodies. Approximately 50% of children under 4 years of age who have IM heterophile antibody have Negative results for this test.
Some segments of the population who contract Infectious Mononucleosis do not produce measurable levels of heterophile antibodies. Approximately 50% of children under 4 years of age who have IM heterophile antibody have Negative results for this test.
Reference Range
Negative
Clinical Significance
Infectious mononucleosis (IM) is an acute, self-limited, lymphoproliferative disease caused by the Epstein-Barr virus (EBV). Infection with EBV usually occurs early in life with no recognizable disease. When primary infection is delayed until young adulthood and adolescence, however, there is about a 50% chance that it will occur with the classic clinical manifestations associated with IM.
The diagnosis of IM is usually based on the evaluation of characteristic clinical, hematological, and serological changes. In most cases of IM, clinical diagnosis can be made from the characteristic triad of fever, pharyngitis, and cervical lymphadenopathy, lasting for 1 to 4 weeks. IM may be complicated by splenomegaly, hepatitis, pericarditis, or central nervous system involvement. Rare fatal primary infections occur in patients with histiocytic hemophagocytic syndrome or with a genetic X-linked lymphoproliferative syndrome. Hematologic features of IM include lymphocytosis with prominent atypical lymphocytes. Because other diseases may mimic the clinical and hematological symptoms of IM, serological testing is essential for the most accurate diagnosis. Serological diagnosis of IM is demonstrated by the presence of heterophile and EBV antibodies in the sera of patients.
The diagnosis of IM is usually based on the evaluation of characteristic clinical, hematological, and serological changes. In most cases of IM, clinical diagnosis can be made from the characteristic triad of fever, pharyngitis, and cervical lymphadenopathy, lasting for 1 to 4 weeks. IM may be complicated by splenomegaly, hepatitis, pericarditis, or central nervous system involvement. Rare fatal primary infections occur in patients with histiocytic hemophagocytic syndrome or with a genetic X-linked lymphoproliferative syndrome. Hematologic features of IM include lymphocytosis with prominent atypical lymphocytes. Because other diseases may mimic the clinical and hematological symptoms of IM, serological testing is essential for the most accurate diagnosis. Serological diagnosis of IM is demonstrated by the presence of heterophile and EBV antibodies in the sera of patients.
Performing Laboratory
HHN / HHI Laboratory
